体细胞突变
艾滋病疫苗
生发中心
启动(农业)
病毒学
免疫学
抗体
接种疫苗
生殖系
生物
免疫球蛋白类转换
中和抗体
B细胞
疫苗试验
遗传学
基因
发芽
植物
作者
David J. Leggat,Kristen W. Cohen,Jordan R. Willis,William J. Fulp,Allan C. deCamp,Oleksandr Kalyuzhniy,Christopher A. Cottrell,Sergey Menis,Greg Finak,Lamar Ballweber-Fleming,Abhinaya Srikanth,Jason R. Plyler,Torben Schiffner,Alessia Liguori,Farhad Rahaman,Angela Lombardo,Vincent Philiponis,Rachael E. Whaley,Aaron Seese,Joshua Brand
出处
期刊:Science
[American Association for the Advancement of Science]
日期:2022-12-01
卷期号:378 (6623)
被引量:171
标识
DOI:10.1126/science.add6502
摘要
Broadly neutralizing antibodies (bnAbs) can protect against HIV infection but have not been induced by human vaccination. A key barrier to bnAb induction is vaccine priming of rare bnAb-precursor B cells. In a randomized, double-blind, placebo-controlled phase 1 clinical trial, the HIV vaccine-priming candidate eOD-GT8 60mer adjuvanted with AS01
科研通智能强力驱动
Strongly Powered by AbleSci AI